Netasudil Dimesylate

 Netarsudil Dimesylate

一、Product Overview

      Netarsudil Dimesylate, developed by Aerie Pharmaceuticals as a drug for glaucoma or high intraocular pressure, was approved by the us food and drug administration (FDA) on December 18, 2017. The compound's patent expires in 2026.

二、Main products

Description	Structural Formula	CAS No.	Category
Netarsudil Dimesylate		1422144-42-0	API
(S)-3-((tert-butoxycarbonyl)amino)-2-(4-(((2,4-dimethylbenzoyl)oxy)methyl)phenyl)propanoic   acid		2097334-20-6	Intermediate
isoquinolin-6-amine		23687-26-5	Intermediate
(S)-4-(3-((tert-butoxycarbonyl)amino)-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl   2,4-dimethylbenzoate		1253955-19-9	Intermediate

Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes patent infringement and its liability is at buyer's risk.